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1. Introduction 
Schistosomiasis also known as Bilharziasis, is a parasitic disease that dates back to antiquity. 
The ancient Egyptians, through settling and cultivating the Nile valley, were among the first 
to contract the disease. Thus, the main symptom hematuria was mentioned in Egyptian 
papyri (1500-1800 B.C.), and schistosome eggs were identified in Egyptian mummies 
through paleopathologic studies. In 1852, Theodor Bilharz, a German pathologist working in 
Cairo, discovered the worms in the portal circulation and was the first to describe the 
Pathology of the disease. Ferguson in 1911 was the first to report on the high frequency of 
bladder cancer in Egypt and to suggest an etiologic relation with urinary Schistosomiasis, a 
fact which is now generally accepted (Bolkainy & Chu 1981a). The aim of this article is to 
review the pathobiology of Schistosoma associated bladder cancer (SACB), describe the 
relationship between Schistiosomiasis and bladder cancer with respect to the mechanisms of 
carcinogenesis with emphasis on special features of SABC and recent methods of early 
detection. 
2. Incidence and risk factors  
An estimated 386,300 new cases and 150,200 deaths from bladder cancer occurred in 2008 
worldwide ( Jemal  et al.,2011). The majority of bladder cancer occurs in males and there is a 
14-fold variation in incidence internationally. The highest incidence rates are found in the 
countries of Europe, North America, and Northern Africa. Egyptian males have the highest 
mortality rates (16.3 per 100,000), which is twice as high as the highest rates in Europe (8.3 in 
Spain and 8.0 in Poland) and over 4 times higher than that in the United States (Ferlay et al., 
2010) Smoking and occupational exposures are the major risk factors in Western countries, 
whereas chronic infection with Schistosoma hematobium in developing countries, particularly 
in Africa and the Middle East, accounts for about 50% of the total burden.(Parkin,2006)  A 
majority of bladder cancers associated with schistosomiasis are squamous cell carcinoma, 
(SCC) while those associated with smoking are transitional cell carcinoma (TCC)  (Sliverman 
et al.,2006).In the United States, mortality rates have stabilized in males and decreased in 
females from 1997 through 2006, (Edwards  et al.2010) and in Europe declines have been 
observed in most countries since the 1990s, (Karim-Kos et al.,2008) due in part to reductions 
in smoking prevalence and reductions in occupational exposures known to cause bladder 
cancer. Bladder cancer continues to be the most common cancer among males in Egypt 
(Ferlay et al.2010),  despite the large decreases in schistosomiasis.This is likely the result of a 
reduction in schistosoma-related bladder cancers being offset by an increase in tobacco-
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related bladder cancers.(Althuis  et al., 2005). The association with Schistosomiasis determines 
a distinct clinico-pathologic entity quite different from that experienced in the Western 
world. It is commonly a well-differentiated SCC (80 %) with a limited tendency to lymphatic 
and blood stream metastasis despite the locally advanced stage of tumors in the majority of 
patients. Compared with Western series the tumors are multiple in 22% of cases and are 
frequently associated with atypical epithelial changes in the rest of the urothelium. SABC 
was encountered at an earlier age in patients with schistosome eggs in the specimens. About 
95% of cases are muscle invasive at the time of presentation and, in absence of effective 
systemic therapy, these cases are often fatal. In fact, until recently, SABC has been the most 
common cause of death among men age 20– 44 years (Freedman et al.,2006). Schistosomiasis, 
is now a widespread endemic disease currently found in 75 countries. In the Nile Delta area, 
mixed infection with S. haematobium and S. mansoni is endemic, while S. haematobium is 
more prevalent in Upper Egypt due to the greater abundance of the specific intermediate 
host snails in that area. In schistosomiasis due to S. haematobium, the intensity of infection is 
correlated with morbidity, the degree of hematuria and proteinuria, and the pathological 
changes observed in the urinary bladder and ureters and malignancies of the bladder. The 
evidence associating S. haematobium infection with the development of bladder cancer is, 
however, far greater than that for any other parasitic infection; it has been supported by 
several major studies in countries in Africa and the Middle East ( Moustafa et al.,1999). 
Cigarette smoking is now recognized as a major cause of bladder cancer in developed 
countries, increasing the risk two to three fold in North America and Europe and accounting 
for 50% of these cancers in males and 25% in females. Although much less information is 
available from developing countries, a recent study in Egypt indicated that smoking was 
strongly associated with bladder cancer in males and could account, at least in part, for 75% 
of these cancers (Freedman et al.,2006). Other risk factors includes  certain organic chemicals 
– particularly aromatic (aryl)-amines such as naphthalene, benzidine, aniline dyes, and 4- 
aminobiphenyl – are known bladder carcinogens and have helped identify high-risk 
occupations, including petroleum chemical/rubber workers, hairdressers, painters, textile 
workers, truck drivers, and aluminum electroplaters. Bladder cancer may also result from 
pelvic radiotherapy, phenacetin use, and cyclophosphamide exposure, resulting in a four- to 
five-fold relative risk increase, particularly when exposure is in a chronic low-dose form 
(Ibrahim & Khaled,2006). 
3. Evidence supporting the relationship between schistosomiasis and 
bladder cancer  
3.1 Epidemiological evidence 
The association of bladder cancer with schistosomiasis seems to be related to the endemicity 
of the parasite. Urinary Schistosomiasis is endemic throughout most of Africa, the Middle 
East, Madagascar, Reunion, Mauritius and India. In Africa, a high frequency is reported in 
countries along river Nile such as Egypt and Sudan, as well as, countries around lake 
Victoria as Kenya and Uganda. The disease is also prevalent in the west of the continent 
(Gold Coast and Senegal) and the eastern side of the continent below the Equator 
(Mozambique, Zambia and New Guinea) (Moustafa,et al.,1999). In the Middle East, it occurs 
in Iraq, Iran, Syria, Saudi Arabia and Yemen (Al-Saleem et al.,1990, Al-Shukri et al.,1987,  
Elem, & Purohit,1983).The consensus of available information strongly implicates an 
association between S. haematobium infection and the induction of bladder cancer. In Egypt, 
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bladder cancer has been the most common cancer during the past 50 years. In 2002, Egypt’s 
World-standardized bladder cancer incidence was 37/ 100,000, representing approximately 
30,000 new cases each year( Parkin et al.,2005). Interestingly, the most common 
histopathological type of bladder cancer in Egypt has been SCC, constituting from 59% to 
81% of reported bladder cancers between 1960 and 1980 (El-Mawla  et al.,2001). Contrary to 
the leading etiology of smoking and occupational exposures in Western countries, chronic 
bladder infection with Schistosoma haematobium, the nematode causing urinary 
schistosomiasis, has been the most important risk factor for bladder cancer in Egypt 
(Moustafa et al.1999)  This neoplasm accounts for 30.8% of the total cancer incidence and is 
ranked first among all types of cancer recorded in Egyptian males and second only to breast 
cancer in females  (Mokhar et al.,2007). Changes in exposures linked to bladder cancer have 
occurred recently in Egypt. Prior to the 1964 completion of the Aswan High Dam, 
approximately 60%of people in North and South Egypt were infected with S. haematobium; 
a similar proportion was infected with S. mansoni (causing intestinal disease) in North 
Egypt, but rarely seen in southern parts of the country( El-Khoby et al.,2000). The dam 
appears to be responsible for a gradual replacement of S. haematobium by S. mansoni in North 
Egypt, and S. mansoni has expanded into southern regions (Felix et al.,2008). Another change 
in bladder cancer risk involves rising cigarette smoking in Egypt, which is now 32% among 
males (but only 7% among females) ( WHO, 2000). In other countries, such as Iraq, Malawi, 
Zambia and Kuwait, where the endemicity of schistosomiasis due to either mixed or S. 
haematobium infestations is high, bladder cancer was also reported to be the leading cancer 
(Felix et al.,2008). In contrast, in schistosome-free countries bladder carcinoma ranks from the 
5th to the 7th most common cancer in men and from the 7th to the 14th in women (Moustafa 
et al. 1999). With the reduction in schistosomiasis due to control efforts over the past 30–40 
years, the epidemiology of bladder cancer in Egypt has shifted dramatically. This is 
exemplified by a recent study from Gouda et al (2007 ) in which they reviewed 9843 patients 
treated for bladder cancer by Egypt’s National Cancer Institute (NCI) in Cairo between 1970 
and 2007. The authors identified a dramatic decline in the proportion of patients with 
bladder cancer who had schistosoma ova on pathological evaluation (82.4% vs 55.3%) and in 
the proportion of patients treated for bladder cancer (from 27.6% of patients treated for 
cancer to 11.7%). They also describe an increase in the median age at presentation (from 47.4 
years to 60.5 years), a decrease in the male to female ratio (from 5.4 to 3.3) and a decrease in 
the proportion of patients with SCC histology (from 75.9% to 33.0%). A similarly designed 
study from the Egyptian NCI in Cairo showed that patients treated for bladder cancer in 
2005 had a six-fold increased risk of TCC  of the bladder (vs SCC) compared with patients 
treated in 1980 ( Felix et al.,2008)  They also evaluated the incidence of SABC at several other 
institutions in Egypt during this period and showed no rise in incidence at other institutions 
as the incidence decreased at the NCI. Furthermore, these epidemiological trends have also 
been documented in the Egyptian nation-wide tumor registries (Salem et al., 2000, 
Freedman et al., 2006). The increase in frequency of TCC and decrease in frequency of SCC 
relative to previous reports indicate a transition phase from the SABC to the Western type of 
bladder cancer related to smoking, exposure to occupational  and  agricultural related 
chemicals. (Ibrahim & Khaled, 2006) 
3.2 Experimentally induced schistiosomiasis 
Several attempts were made to evaluate the carcinogenic potential of experimentally 
induced schistosomiasis. It has been suggested that chronic tissue injury could provide a 
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promoting factor which acts to increase the rate of cell turnover via the induction of 
restorative hyperplasia and squamous metaplasia. Most of this focal hyperplasia is 
subsequently reversible However, in some situations, hyperplasia and dysplasia may 
become irreversible, particularly during concomitant exposure to low (sub-carcinogenic) 
doses of carcinogens e.g., N-nitroso compounds (Hicks,.et al., 1980). 
3.2.1 Inflammatory cells  
Schistosomiasis induces chronic irritation and inflammation in the urinary bladder, and this 
could facilitate changes in at least two stages of the development of the disease: first, 
initiation of premalignant lesions, and second, action as a promoting agent to increase the 
likelihood of the conversion of these lesions to the malignant state. At the stage of initiation, 
activated macrophages induced at the sites of inflammation are implicated in the generation 
of carcinogenic N-nitrosamines (NNA )and reactive oxygen radicals ( Moustafa et al., 1994) 
that lead to DNA damage and subsequently to events such as mutations, DNA strand 
breaks, and sister chromatid exchanges. Inflammatory cells have also been shown to 
participate in the activation of other bladder carcinogens such as the aromatic amines 
(Badawi et al., 1992, 1995a).  
3.2.2 Bacterial infections 
Various species of bacteria including nitrate –reducing bacteria have been found in greater 
numbers in the urine of patients with schistosomiasis than in the urine of uninfected patients 
(Mostafa et al.1994 ). These higher levels of infection probably result from the tissue damage 
caused in various parts of the urinary tract by the egg-laying activities of the worms 
(Lehman et al.,1973, Falagas et al.2010). Injury to the urothelium from the passing eggs 
and/or bacterial infection might decrease the effectiveness of the mucosal barrier to 
reabsorb carcinogens in urine. Several of these bacterial species can mediate the N-
nitrosation of amines, thereby providing a source of carcinogenic NNA in addition to those 
from exogenous sources (EL-Merzabani et al.,1979,  Moustafa 1999).  
3.2.3 N-Nitrosamines  
Attention has focused on nitrite and N-nitroso compounds (NNCs).(Badawi et al.1995a)   
NNCs can be formed endogenously following the secondary infection by nitrate-reducing 
bacteria that invariably accompany schistosomal cystitis. NNCs, including nitrosamines and 
the direct-acting nitrosamides, are carcinogenic, inducing tumorigenic alkylation of specific 
bases and DNA sequences(O’Brien  et al., 1988, Badawi et al.,1993,1994 ). Evidence of the 
interaction of carcinogens, with the genetic material of the bladder has been obtained by 
analyzing bladder mucosal DNA for the presence of mutations ( Marletta,1988,Badawi et 
al.,1995b). Mutations have been observed in oncogenes, tumor suppressor genes, and genes 
associated with cell cycle control. In particular, mutations in the tumor suppressor gene p53 
have been observed more frequently in patients with SABC than in patients with non-SABC( 
Badawi 1996). Changes in these and other genes and in microsatellite DNA, presumably 
arising as a result of carcinogenic insults, may lead to greater genetic instability and hence to 
the malignant transformation ( Yamamoto, et al., 1997). Genomic DNA hypomethylation has 
been recently suggested as biomarker for to identify individuals who are more susceptible 
to the development of bladder cancer  (Theodorescu 2003) Moreover, Inflammatory cells 
also participate in the activation of procarcinogens, such as aromatic amines and polycyclic 
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aromatic hydrocarbons, to their ultimate carcinogenic metabolites (i.e., the final reactive 
form of the carcinogen) (Badawi et al.,1993). Since the aromatic amines are an important 
group of bladder carcinogens, an increased number of inflammatory cells in the urinary 
bladder of schistosomal patients may enhance the carcinogenic potential of these agents by 
increasing their rate of activation (Moustafa et al., 1994). 
3.2.4 Cigarette smoking  
Tobacco use is a well-documented risk factor for developing bladder cancer, but specific 
carcinogen(s) and molecular pathway(s) have not been elucidated. Much interest has 
focused on aromatic amines such as 4-aminobiphenyl (ABP) because they are found not 
only in cigarette smoke but also in several industrial chemicals. One potential mechanism by 
which amines cause carcinogenesis is by forming DNA adducts that result in transitional 
mutations(  Kadlubar & Badawi  1995, Kaderlik, & Kadlubar 1995,). Habuchi et al., 1993 
suggested that cigarette smoking might have a significant impact on the mutations of the 
p53 gene in urothelial cancers. Urothelial carcinogenesis in the presence of schistosomiasis 
seems to proceed along pathways different from those linked to smoking, since cigarette 
smoking appears to have a significant impact on the mutation of the p53 gene with A:T to 
G:C transitions which are not observed in SABC (Habuchi et al., 1993). The association of 
human papilloma virus (HPV) and non-schistosomal bladder squamous cell cancers has 
been reported in isolated cases in the USA (Maloney et al., 1994). An Egyptian study has 
also demonstrated HPV DNA in six of 16 (38%) SABC (Zekri  et al.,1995). While SABC in 
South Africa showed no associated HPV (Cooper et al.,1997).  
3.2.5 Occupational exposure 
Exposure to chemicals used in dye, rubber, and textile manufacturing have been estimated 
to be responsible for up to 20% of bladder cancer  cases (Cole et al.,1972). Most of these 
chemicals are aromatic amines that take several years to accumulate and thus account for 
the long latent periods before the development of bladder cancer. Aromatic amines from 
occupational exposures are activated and detoxified through the same reactions that 
aromatic amines in cigarette smoke are activated and detoxified. Hence, bladder cancer  
susceptibility depends on the cumulative expression profiles of these activating and 
detoxifying enzymes. It also means that exposures to occupational agents and cigarette 
smoke may be additive ( Jung & Messing, 2000). 
3.3 Genetic changes 
The major differences in the clinico-pathologic features observed between the Western type 
of bladder cancer and SABC probably reflect underlying alternate tumor biology and 
carcinogenic pathways. Several studies attempted to characterize the chromosomal 
aberrations of SABC, including both SCC and TCC subtypes. Data were compared with 
those of the Western world.  
3.3.1 Chromosomal studies  
Over representation of 5p,6p,7p,8q,11q,17q and 22q of chromosomal material has been 
detected by Cytogenetic and molecular analysis. Aberrations of chromosomes 7, 9, and 17 
showed reciprocal patterns in TCC and SCC, whether associated with Schistiosomiasis or 
not (Pycha et al. 1998). Few sporadic SCC cases examined by comparative genomic 
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hybridization (CGH) have shown gains at 1q, 8qa, and 20q, as well as loses of 3p,9p, and 13q 
(El-Rifai et al.2000). Changes were observed at similar frequencies in SCC and TCC, 
irrespective to schistosomal status suggesting that these changes may be involved in a 
common pathway for bladder cancer development and progression independent of 
schistosomal status or histological subtype ( Badawi,1996).  
3.3.2 Cancer genes 
Currently, it would appear that chromosome 9 and P53 changes may occur relatively early 
in the genesis of bladder cancer (Simoneau et al., 1996 , Reznikoff et al., 1996). The 
retinoblastoma (Rb) gene on chromosome 13 (13q) and the p53 gene on chromosome 17 
(17p) play an important role in the progression of bladder cancer and possibly its 
development (Esrig et al., 1994). Rb gene mutations are seen in approximately 30% of 
bladder cancer (Cordon cardo et al.,1992). Inability to detect pRb immunohistochemically is 
associated with increased tumor grade and stage, especially muscle invasion ( Xu et. 
al.,1993, Grossman et al.,1993 ) Some Studies revealed that Allelic losses in chromosome 17p, 
where the p53 gene resides, were less frequent in SCC (38%) than TCC (60%) Gonzalez-
Zulueta,1995 while in South Africa, p53 mutations were recorded in 57% of SABC. (Badawi  
et al. 1999). It was also demonstrated that the histopathological subtype rather than the 
schistosomal impact itself determines the pattern of chromosomal changes for SABC. The 
pattern of point mutations in p53 appears to reflect the site of tumor origin, with most of the 
transitions occur in mutational hot spots at CpG dinucleotides (Hollstein et al., 1991). TP53 
mutations in  SABC  included  more base  transition at  CpG  dinucleotids than seen in 
urothelial  TCC. p53 inactivation ranged from 0 to 38% at the early stage of the disease, as 
opposed to 33% to 86% in the advanced tumor stage (Weintraub  et al.1995, Badawi  et al. 
1996,) Excess mutations might be due to high levels of urinary nitrates in Schistoma infected  
patients producing nitric oxide by inflammatory cells. In these cases, there is usually an 
overexpression of MDM2 as well (Osman et al.1997). Elevated levels of DNA alkylation 
damage have been detected in schistosome-infected bladders and are accompanied by an 
inefficient capacity of DNA repair mechanisms. Whereas the p53 mutation frequency in SCC 
was similar to that reported for invasive TCC, there were differences in the type and position 
of these mutations between the two tumor types (Gonzalez-Zulueta et al., 1995 ). The ras 
oncogene does not seem to be strongly implicated in the differential process of carcinogenesis 
in SABC, judging from studies in different countries (Czerniak et al., 1990, Ibrahim & 
Khaled,2006). Deletions on chromosome 9 not only appear to occur in > 60% of bladder cancer 
across all grades and stages, but also are likely an initiating event (Jung & messing 2000). The 
p21 region of chromosome 9 (9p21) has been found to be mutated in a variety of malignancies 
suggesting the presence of a common tumor suppressor gene.(Theodorescu, 2003 ). Tamimi et 
al.(1996)   found that a p16INK4 deletion was present in 23 of 47 samples from SABC patients 
and that mutations were present in another 2 patients (i.e; 53% of tumors exhibited p16INK4 
gene alterations). They concluded that p16 INK4 alterations are more frequent in SABC than in 
other bladder tumors and may thus be associated with a specific etiology. 
3.3.3 Microsatellite Instability 
Microsatellite abnormalities found in cancer bladder appear to be early changes 
(Linnenbach et al., 1994; Orlow et al., 1994, Gonzalez-Zulueta et al., 1995), they may be 
reflecting severe deregulation of cellular DNA which if left unchecked may lead to 
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unrepaired mutations in key regulatory genes such as p53. Importantly, microsatellite 
alterations are common in bladder cancer and analysis of genomic instabilities in urine 
samples has been recently evaluated as a method for bladder cancer screening with 
promising results in terms of sensitivity, specificity compared to classical techniques (Seripa 
et al., 2001; Zhang et al., 2001; Berger et al., 2002; Utting et al., 2002). 
3.3.4 Oncogenes 
Oncogenes may contribute to transformation and progression by being either overexpressed 
or mutated to produce an oncoprotein. One of the more important mechanisms by which 
oncogenes are overexpressed in bladder Cancer is through gene amplification (increased 
copies of the gene). In small series of SABC HER-2/ neu was overexpressed in  all the 
studied TCC and none  of  SCC studied by Immunohistochemistry (Coombs et al., 1991, 
Cote et al.,1998,  Wishahi,.et al.2000 ).  
3.4 Cancer progression 
Bladder Cancer cells require the acquisition of certain properties prior to being able to grow 
rapidly, invades, and metastasizes. These properties include uncontrolled growth and 
cellular mobility, mediated at least in part via EGF and EGFRs, expression or loss of 
expression of specific cell adhesion molecules, and overproduction of angiogenic factors. 
These factors may be produced by the tumor cells or released by the surrounding 
extracellular matrix or tumor associated stromal cells, or they may be products of 
inflammatory cells that infiltrate tumors. Folkman et al., (1987) using 
immunohistochemistry, increased microvascular density as a surrogate for angiogenesis has 
been found to be associated with tumor progression and decreased overall survival in 
Bladder Cancer patients.( Bochner et al.1995). The association of the apoptosis related 
proteins Bcl-2, Bcl-x, Bax and Bak, p53, E-cadherin, epidermal growth factor receptor and c-
erbB-2, OCNA and Ki-67 were correlated with the clinical outcome of SACB  in  Cystectomy 
specimens from 109 patients with organ confined, muscle invasive stage, pT2pN0M0 were 
studied by  Haitel and coworkers (2001)  Immunohistochemical results were correlated with 
tumor progression. On multivariate analysis p53 emerged as a significant prognostic factor 
Additional independent prognostic factors were proliferating cell nuclear antigen for 
squamous cell carcinoma, and MIB-1, Bcl-x and Bax for transitional cell carcinoma.  
4. Age and gender ratios  
In schistosome-free countries throughout the world, the peak incidence of bladder cancer is in 
the sixth or seventh decade of life (La Vecchia et al.,  1991) and is maximal between the ages 
of 65 and 75 years). Only 12% of bladder cancer cases occur in people younger than 50 years( 
Burnham, 1989). By contrast, in Egypt, Sudan, Iraq, Zambia, Malawi, and Zimbabwe, the 
mean age of the highest incidence of SABC is between 40 and 49 years (Moustafa et al., 
1999), which clearly contrasts with the findings for non-schistosoma areas. The ratio of 
bladder cancer incidence (males to females) in countries with endemic infection was 
reported to be 5:1 but may vary within the range of 4:1 to 5.9:1 (Ibrahim,1986). The relatively 
higher gender ratio in the countries with endemic infection has been suggested to be 
because in rural areas the main route for infection is through contact with infected waters 
during agricultural activities, which are normally done by men rather than women. The 
predominantly male development of SABC has been explained by the high frequency of loss 
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of chromosome Y using the FISH technique. Khaled et al.,(2000) demonstrated that 41% of 
cases of SABC showed loss of chromosome Y. 
5. Pathobiology of schistosoma associated bladder cancer  
SABC is histopathologically distinct from non-S. haematobium associated bladder cancer that 
occurs in North America and Europe. The former cancer is usually, sparing the bladder’s 
trigone. Although the majority of bladder tumors formed due to Schistosoma infection are 
squamous cell carcinomas (SCC), adenocarcinomas and transitional cell carcinomas (TCC) or 
undifferentiated carcinomas can develop (Johansson &  Cohen, 1997 ) Furthermore, it appears 
that there is a proportional increase of TCC due to schistosomal infections over time (Koraitim 
et al.,1995). Some researchers believe that TCC need more time to progress than SCC and are 
closely related with a less devastating inflammatory infiltrate (Michaud et al., 2007). 
5.1 Gross features  
The tumors commonly appeared as large nodular masses (Figure. 1) whereas papillary 
types are rare (2%). The carcinoma usually arises from the upper vesical hemisphere, at the 
posterior wall or vault. The trigone is rarely the site of the tumor origin (2%)  ( Khafagy et 
al.,1972) in contradistinction to the non-shistosoma associated cancer bladder where it 
involved in 21% ( Mostofi,1975). 
 
 
Fig. 1. SABC nodular type associated with leucoplakia  
5.2 Precursor lesions  
In the Schistosoma infested urinary bladder, the urothelium usually undergoes various 
metaplastic, proliferative and atypical changes ( Khafagy et al.,  1972). Metaplasia refers to a 
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change in cell type, and this explains the histogenesis of non-transitional tumors in the 
bladder. Thus SCC and adenocarcinoma arise on top of squamous metaplasia and columnar 
metaplasia respectively. It is important to distinguish simple hyperplasia of the urothelium 
from atypical lesions (dysplasia and carcinoma insitu). The former is a simple reversible 
change, but the latter are associated with an increased risk of neoplastic development. 
Dysplasia, or low grade intraurothelial neoplasia, referred to pre-neoplastic atypical 
epithelial changes short of frank malignancy. Conversely, carcinoma insitu (CIS), or high 
grade intraurothelial neoplasia, is a preneoplastic atypical lesion which is cytologically 
 
 
                                         (A)                (B) 
 
 
                                         (C)                (D) 
 
 
                                         (E)                (F) 
Fig. 2. A) Simple Squamous metaplasia. B) Cystitis glandularis & cystica. C) Schistosoma 
worm in a vein. D) Squamous dysplasia. E) CIS in Brunn’s nest F) SAB- Squamous cell 
carcinoma grade I. 
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indistinguishable from invasive cancer, but without invasion of the basement membrane. 
The rate of progression to invasive cancer is 15 % in cases of dysplasia (Cheng et al., 2000) 
and 35 % in CIS (Cheng et al., 1999). The SABC is frequently associated with a variety of 
pathologic changes in the bladder mucosa including: leucoplakia, cystitis cystica, carcinoma 
in situ and different schistosoma lesions (Zahran et al., 1976). In a series of Khafagy et al., 
(1972) of SABC 26 % of cases showed  squamous metaplasia, 53 %  of these  lesions were 
non-keratinizing and 29  % showed surface keratinization and 18 % showed basal cell 
hyperplasia and atypia (Figure. 2). 
Columnar metaplasia in the form of Brunn’s nests, cystitis glandularis and cystica was 
observed in 52%-63 % (Khafagy,et al.,  1972 & Zahran et al., 1976) of  cystectomy specimens. 
Cystitis glandularis with atypia has been described by El-Bolkainy & Chu (1981a) at the 
tumor margin of adenocarcinoma. The natural history of these proliferative lesions has not 
been adequately studied due to lack of prospective follow up evaluation. Some of these 
changes such as simple hyperplasia and non- keratinizing squamous metaplasia without 
atypia are probably benign, however there is considerable evidence that atypical forms 
especially keratinizing squamous metaplasia (leucoplakia) may in fact have a premalignant 
potential. Similar evolutions may be expected in simple and atypical lesions of transitional 
epithelium. (Weiner et al., 1997). 
5.3 Tumor histologic types  
The urothelium is a multipotential unstable epithelium hence the multiple tumor types 
which may arise from it.  
5.3.1 Transitional cell Carcinoma 
In the SABC, transitional cell carcinoma contributed about 25 % of cases in large series 
collected over several years (Ghoneim et al., 1997), but there has been an increase in its 
relative frequency in recent years (Table 1). Three histologic subtypes and 10 rare variants 
are recognized. 
 
Years 
No. of patients  
(1976-1978) 
1059 
(1991-1993) 
1256 
(2000-2002) 
923 
Squamous carcinoma 
Transitional carcinoma 
Adenocarcinoma 
Undifferentiated 
78% 
16% 
4% 
2% 
53% 
36% 
6% 
5% 
40% 
49% 
5% 
6% 
Schistosoma ova  82% 59% 52% 
Table 1. Time trend analysis of histologic types of bladder carcinomas in cystectomy 
specimens ( Zaghloul et al., 2008). 
5.3.2 Papillary transitional neoplasm of low malignant potential 
This type is a papillary noninvasive tumor (Ta) which resembles a papilloma but with 
epithelial thickening exceeding the normal 6 layers. It contributes about 20% of all papillary 
tumors. Histologically, it shows preserved normal cell polarity with intact umbrella cells 
and intact basement membrane, no cellular atypia, and infrequent mitosis restricted to basal 
cell layer. Rarely may it show a prominent endophytic or inverted pattern. Such tumors 
were previously classified as grade I TCC. However, long term follow up studies have 
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confirmed its rather benign nature. Thus, whereas 52 % of cases recurred, only 2% 
progressed to muscle invasive, and hence are considered favorable tumors of borderline 
malignancy or very low malignant potential. 
5.3.3 Papillary transitional carcinoma 
This refers to papillary tumors, which are composed partially, or entirely of malignant 
transitional epithelium. This type may be invasive or noninvasive. It is usually exophytic in 
pattern, rarely endophytic. Histologically, it shows both architectural disorder, as well as, 
cellular atypia of variable degree. They are graded either on a scale of three or a scale of two 
(low and high grades).  
5.3.4 Invasive transitional carcinoma 
This describes a non-papillary urothelial carcinoma (Figure.3) that invades the bladder wall; 
hence an aggressive behavior is expected. Such invasive property may complicate a 
papillary tumor, or may arise de novo. Also, these tumors are graded either on a scale of 3, 
or a scale of 2 (low and high grades). For therapeutic and prognostic implications, it is 
important to describe the pattern of invasion at tumor margin, namely: expansile with 
broad-front or tentacular growth, as well as, the depth of invasion, namely: infiltration of 
lamina propria(focal or extensive) or muscularis propria. In SABC the majority of tumors 
are invasive and 86% are high grade (Ghoneim et al., 2008).  
5.3.5 Squamous Cell Carcinoma 
The high frequency of SCC is one of the main distinctive features of carcinoma in the SABC 
and has been noted for a long time in different reports from Egypt, A relative frequency of 
59% was recently reported (Ghoneim et al., 1997, 2008). This contrasts sharply with the 
relative infrequency of true squamous cell carcinoma in the Western world, which varied 
between 3% and 7% (El-Bolkainy et al., 1981b). The predominance of SCC  in SACB series is 
probably related to squamous metaplasia and dysplasia which are relatively common in 
chronic Schistosomal cystitis that are frequently associated (65%) with this type of 
carcinoma (Khafagy et al.,1972). Fibrosis of the bladder wall of schistosomal origin has long 
been suspected as a limiting factor against tumor spread. Tissue reactions to schistosome 
eggs in the bladder wall, pelvic lymphatics, and regional lymph nodes were proposed as 
limiting factors against neoplastic spread. However the limited tendency of lymphatic 
spread of advanced tumors in schistosomal patients was explained by others as caused by 
predominance of low grade tumors in these patients (El-Bolkainy et al., 1981b). 
Histologically, SCC is composed of one cell type exhibiting squamous differentiation 
throughout the tumor. Malignant squamous cells may exhibit one or more of the following 
features according to their grade: eosinophilic cytoplasm, sharp cell borders, intercellular 
bridges, and concentric cellular formations of cell nests (squamous pearls). In bilharzial 
series, one half of cases are grade 1 or low grade with numerous cell nests and only slight 
nuclear anaplasia  
5.3.6 Verrucous carcinoma  
This rare variant of SCC, which has only been reported to occur in the schistosomal bladder, 
(Figure 4) is characterized by a low-grade malignancy and absence of lymph node or distant 
spread. It contributing 4.6% of SCC or 3.4% of all types of SABC (El-sebai, 1978)). 
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Fig. 3. A) Squamous cell carcinoma. B) Squamous cell carcinoma, urinary bladder. Notice 
the Schistosoma ova. C) Transitional cell carcinoma. D) Transitional cell carcinoma, Notice 
the vaible Schistosoma ova. E) Adenocarcinoma intestinal type. F) Mucinous 
adenocarcinoma 
Verrucous carcinomas are divided into pure form which is exceptionally rare, and verrucous 
carcinoma associated with an invasive component (verrucoid carcinoma) which is more 
common. The former is a tumor of low malignant potential, but the latter will rather behave 
as conventional squamous cell carcinoma. Histologically, the tumor is a well differentiated, 
hyperkeratotic squamous cell carcinoma with elongated surface projections and down 
growths of club-shaped finger-like processes. The deeply advancing margin has a pushing 
rather than infiltrating border, where the cells are arranged in large bulbous masses of 
cohesive squamous cells.  
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Fig. 4. SABC verrucous carcinoma cystectomy & cut section. Courtesy El-Bolkainy 
5.3.7 Rare variants 
The decline in the prevalence of Schistosomiasis in Egypt during the past two decades was 
associated with significant changes in the pathology of bladder carcinoma. This was 
confirmed by a time trend analysis study which demonstrated a significant decrease in 
Schistosoma eggs in tissues, a decline in the relative frequency of squamous carcinoma and 
an increase of transitional carcinoma (Zaghloul et al., 2008). Ten unusual variants of 
urothelial carcinomas are recognized (Mostofi et al.,1975), namely: urothelial carcinoma 
with squamous or glandular metaplasia, urothelial carcinoma with lymphocytic infiltrate 
(lymphoepithelioma), urothelial carcinoma clear cell type, urothelial carcinoma with ectopic 
placental glycoprotein  production, plasmacytoid variant, lipid cell variant, micropapillary 
variant nested or deceptively benign variant, microcystic variant and osteoclastic variant. 
5.3.8 Adenocarcinoma 
Primary adenocarcinoma arises on top of cystitis glandularis, and is a rare tumor in western 
literature with a reported incidence of about 2%. This tumor type is more frequently 
encountered in areas where Schistosomiasis is endemic with a reported frequency variable 
between 6% (El-Bolkainy et al., 1981a) and 11% (Ghoneim et al.,1997). In a series of 185 
patients of Schistosoma -associated primary adenocarcinoma, (El-Mekresh et al.,1998) 32% 
were non-mucin producing enteric type ( Figure 3), 54% with interstitial mucin production, 
10% with intraluminal mucin and 4% with intracellular mucin or signet ring type. 
5.3.9 Undifferentiated tumors 
About 2% of bladder carcinomas are too undifferentiated to be included in any of the above-
mentioned histologic types. This heterogeneous group is generally highly aggressive and 
associated with very poor prognosis. It includes: small cell carcinoma, spindle and giant cell 
carcinoma and carcinosarcoma.  
6. Early detection  
Current methods of investigation of bladder cancer involve cystoscopy, ultrasound scanning 
and contrast urography, with additional information provided by cytology. These methods, 
although having a high detection rate, are expensive, time-consuming, invasive and 
uncomfortable.  
www.intechopen.com
 Schistosomiasis 
 
156 
6.1 Urine cytology  
Cytology of voided urine or bladder washes is the most established noninvasive method in 
the work-up of haematuria (the most common presentation of bladder cancer) and follow-
up in patients with a history of bladder cancer and is used as an adjunct to cystoscopy. This 
involves microscopic identification of exfoliated tumor cells based on cytological criteria 
(Figure 5). El-Bolkainy and Chu (1981a) used urine cytology for selective screening of rural 
high –risk population from 15 villages in Nile delta in Egypt for early detection of SABC. 
The high-risk group included farmers aged 20 years and above, and they contributed 19% of 
the total rural population. The tumor yield was 2 per 1000 high-risk screened and the 
majority of the detected tumors were at an early stage. The method has a high specificity but 
relatively low sensitivity, particularly in well-differentiated bladder tumors (Carmack & 
Soloway 2006). A meta-analysis that included data on 18 published series with 1,255 patients 
reported a sensitivity of 34% and specificity of 99% respectively (Lotan et al., 2003). Several 
factors contribute to this poor ability of urine cytology to detect cancer cells: only a small 
sample of urine can be processed and only a fraction of the sample can be used for final 
analysis which reduces the chance of capturing tumor cells. Background cells such as 
erythrocytes and leukocytes also confound the cytologic technique. Furthermore, cytological 
criteria that differentiate between low grade tumors and reactive cells can be ambiguous. 
(Wiener et al., 1993) 
6.2 Urinary tumor markers of the bladder  
The low sensitivity of urine cytology limits its use as a detection tool. Interest has been 
reported in identifying tumor markers in voided urine that would provide a more sensitive 
and objective test for tumor recurrence. Detection of bladder cancer using morphologic 
molecular tests could improve patient management in two ways. It would allow diagnosing 
tumors of the aggressive phenotype earlier and thus improve the prognosis of patients. In 
cases of less aggressive tumors, it could identify early disease onset and recurrences, thereby 
potentially reducing the need for expensive cystoscopic monitoring and surveillance 
procedures (Mitra et al., 2009). The following table 2 reflects the sensitivities and specificities 
of urine tumor markers in bladder cancer as reported in various publications 
 
Commercially available marker 
Sensitivity (%)
mean/ range
Specificity (%) 
mean/ range 
Cytology 48/ 16-89 96/ 81-100 
Hematuria dipstick 68/ 40-93 68/ 51-97 
BTA STAT 68/ 53-89 74/ 54-93 
BTA TRAK 61/ 17-78 71/ 51-89 
NMP22 75/ 32-92 75/ 51-94 
NMP22 BLADDER CHEK 55.7 85.7 
IMMUNOCYT 74/ 39-100 80/ 73-84 
UROVYSION 77/ 73-81 98/ 96-100 
Table 2. The sensitivities and specificities of  selected urine tumor markers in bladder cancer 
(Urinary Tumor Markers for Bladder Cancer Corporate Medical Policy available at 
(www.bcbsnc.com ) 
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There are several potential applications of urine tumor marker tests in patient surveillance, 
including: a) serial testing to detect recurrent disease earlier, b) as an adjunct to urine 
cytology in order to improve the detection of disease recurrence, c) providing a less 
expensive and more objective alternative to urine cytology, and d) directing the frequency of 
cystoscopy evaluation in the follow-up of patients with bladder cancer (Mitra, 2010). 
Currently available bladder cancer tumor markers and some of those in development are 
listed in Table 3,4, with an assessment of each marker and the level of evidence (LOE) for its 
clinical use. The LOE grading system is based on that of Hayes et al., (1996)  
 
 
 
 
 
 
                                    (A)                                                                            (B) 
 
 
 
                                    (C)                                                                            (D) 
 
 
 
 
Fig. 5. A) Schistosoma ova terminal spine in urine. B) Squamous cell carcinoma, urine 
cytology. C) Squamous cell carcinoma spindle cell urine cytology. D) Squamous cell 
carcinoma tadpole, urine cytology. 
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Level Type of evidence  
I  Evidence from a single high-powered prospective controlled study 
specifically designed to test the marker, or evidence from a meta-analysis, 
pooled analysis or overview of level II or III studies.  
II  Evidence from a study in which marker data are determined in relationship 
to a prospective therapeutic trial that is performed to test a therapeutic 
hypothesis but not specifically designed to test marker utility.  
III  Evidence from large prospective studies.  
IV  Evidence from small retrospective studies.  
V  Evidence from small pilot studies.  
Table 3. Levels of evidence (LOE) for grading clinical utility of tumor markers  
 
Cancer Marker  LOE 
BTA Stat  II 
BTA Trak  II 
NMP 22  II 
Bladder Chek  II 
Immunocyt  II 
UroVysion  II 
Cytokeratins 8, 18, 19  III 
Telomerase – TRAP, hTert, hTR  III 
BLCA-4  II 
Survivin – protein and mRNA  II 
Microsatellite markers  III 
Hyaluronic acid / hyaluronidase  III 
DD23 monoclonal antibody  II 
Fibronectin  III 
HCG – protein and mRNA  IV 
DNA promotor regions of hypermethylated tumor suppressor and apoptosis 
genes  
IV 
Proteomic profiles  
(Mass spectrometry)  
V 
HCG, human chorionic gonadotropin; HTR, human telomerase; hTERT, human telomerase reverse 
transcriptase; TRAP, telomeric repeat amplification protocol; LOE, Levels of evidence( Fritsche. et 
al.2010 ) 
Table 4. Currently available urine markers for bladder cancer. 
6.2.1 Commercially available bladder tumor biomarkers in urine  
BTA (bladder tumor antigen) stat® test, is a qualitative, point-of-care test with an immediate 
result that identifies a human complement factor H-related protein that was shown to be 
produced by several human bladder cell lines but not by other epithelial cell lines. The BTA 
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stat test is an in vitro immunoassay intended for the qualitative detection of bladder tumor 
associated antigen in urine of persons diagnosed with bladder cancer The BTA stat test is an in 
vitro immunoassay intended for the qualitative detection of bladder tumor associated antigen 
in urine of persons diagnosed with bladder cancer. This test is indicated for use as an aid in the 
diagnosis and monitoring of bladder cancer patients in conjunction with cystoscopy. The BTA 
TRAK® test provides a quantitative determination of the same protein. Both tests have 
sensitivities comparable to that of cytology for high-grade tumors and better than cytology for 
low-grade tumors. Nuclear matrix protein 22 (NMP-22) is a protein associated with the 
nuclear mitotic apparatus. It is thought that this protein is released from the nuclei of tumor 
cells during apoptosis. Normally, only very low levels of NMP-22 can be detected in the urine, 
but elevated levels may be associated with bladder cancer. NMP-22 may be detected in the 
urine using an immunoassay. for use in the initial diagnosis and surveillance of bladder 
cancer. Testing for BTA or NMP-22 has been proposed as an adjunct or alternative to urinary 
cytology as a technique for bladder cancer surveillance. In addition, both tests have been 
investigated as initial tests in patients with signs and symptoms suggestive of bladder cancer ( 
Bas et al.,2009). 
Fluorescence in situ hybridization (FISH) DNA probe technology has also been used to 
detect chromosomal abnormalities in voided urine to assist not only in bladder cancer 
surveillance but also in the initial identification of bladder cancer. fluorescence in situ 
hybridization (FISH)  DNA probe technology is a technique to visualize nucleic acid 
sequences within cells by creating short sequences of fluorescently labeled, single-strand 
DNA, called probes, which match target sequences. The probes bind to complementary 
strands of DNA, allowing for identification of the location of the chromosomes targeted. The 
UroVysion Bladder Cancer Kit designed to detect aneuploidy for chromosomes 3, 7, 17, and 
loss of the 9p21 locus via in urine specimens (Figure 6 ). It is used as an aid for initial 
diagnosis of bladder cancer in patients suspicion of disease, and in conjunction with 
cystoscopy to monitor bladder cancer recurrence. Better performance has been reported in 
identification of carcinoma in situ and high grade tumors (lokeshwar  et al.,2005). Another 
potential advantage is apparent from a study of 69 cases of bladder wash where 3 cases 
showed no visible mass on cystoscopy, urine cytology was negative but was positive by 
FISH (Badawi,  2011). 
The ability of the test in detecting occult tumors that are not initially visible on cystoscopy is 
apparent from finding of chromosomal. (Chromosomal abnormalities detected in exfoliated 
cells in urine of patients under surveillance have preceded cystoscopically identifiable 
bladder tumors by 0.25 to 1 year in 41%-89% patients (Mitra  et al., 2009). The ImmunoCyt™ 
testuses fluorescence immunohistochemistry with antibodies to a mucin glycoprotein and a 
carcinoembryonic antigen (CEA). These antigens are found on bladder tumor cells. It used 
mainly for monitoring bladder cancer recurrence in conjunction with cytology and 
cystoscopy.  
6.2.2 Other urinary markers 
A number of other urinary tumor markers not currently commercially available are under 
investigation (Steiner et al.,1997, Stein et al.,1998).The availability of many new markers for 
bladder cancer raises the possibility of improving the rate of cancer detection by combined 
use of selected markers, measured either simultaneously or sequentially (Sanchez-Carbayo 
et al.,2001). The objective of such panel testing should be to improve both the sensitivity and 
the specificity for bladder cancer detection. 
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(A)     (B) 
Fig. 6. (A) Multicolor FISH  Notice absence of yellow signals denoting 9p21 deletion X1250. 
(B) polysomy of chromosomes 3(red signals), 7 (green signals), and 17 (aqua signals) & 
deletion of chromosome 9p21 (absence of yellow signals X 1000). The background shows 
inflammatory cells with 2 copies of each of the studied chromosomes (normal pattern). 
Courtesy Omnia Badawi. 
7. Prognostic factors  
The major challenges confronting the urologist after treatment of bladder cancer are tumor 
recurrence and progression. In this regard, some pathologic parameters may serve as 
predictors of the biologic behavior of bladder tumors. Such prognostic factors are most 
valuable to stratify patients and to select high-risk patients for adjuvant treatment. 
Transurethral resection is commonly practiced for superficial bladder carcinoma in the west, 
but very rarely in the SABC. In the latter, most of the patients (95.3%) present with muscle 
invasive carcinoma, hence radical cystectomy is the treatment of choice. ( El-Sebai,1978).For 
this reason, we will limit our discussion here for prognostic factors for invasive tumors after 
radical cystectomy, of Schistosoma associated series. 
7.1 Prognosis in SABC  
Ghoneim and associates (2008) analyzed a large series of 2720 cases of bladder cancer in a 
single institution of these 2090 were men and 630 women. The average age was 43 years, 
which is considerably lower than in European and American series. The Median follow up 
was 5.5 years. Schistosoma eggs were found in 85% of the cystectomy specimens. Of particular 
interest is the histology of the tumors removed. Squamous bladder tumors were encountered 
in 59%, transitional cell carcinoma in 22% and adenocarcinomas (non-urachal) were seen in 
11% of the cases. About 7% of the tumors were mixed or unclassified. Nodal involvement has 
been universally associated to a poor outcome. Regional lymph nodes were involved in 20.4%. 
Bilateral lymph node involvement was reported in 39.6%.There is a sentinel region which is 
the endopelvic region. There is no skipped metastasis. Negative nodes in the endopelvic 
region indicate that more proximal dissection is not necessary and bilateral endopelvic 
dissection is required. Lymph node positivity is a significant and independent prognostic 
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factor. The relative risk for the development of treatment failure among node positive patients 
was computed to be 1.8%. The investigators used univariate and multivariate analysis to test 
the following prognostic factors on disease free survival: sex, histology, stage, grade, lymph 
node status and presence or absence of Schistosoma ova. Noteworthy is that they found the 
same results as Bassi et al.(1999)  In the multivariate analysis only tumor stage and grade as 
well as lymph node status had a significant impact on survival. The 5-year survival rate was 
48%, also comparable to other published series (El-Mawla et al., 2001). The problem of correct 
clinical staging was also addressed by the authors. Clinical staging was not correct in 32% of 
the cases with the tendency to under stage the extent of the disease. The 5-year survival was 
55% for lymph node negative patients and only 18% for patients with positive lymph nodes. 
Survival was strongly correlated to the stage of the disease. Stage pT3a patients 5-year survival 
was 43%, for pT3b it was 31% and for pT4 tumors only 8% survived 5 years and 2.6% died 
postoperatively These data are in concordance with data published on cystectomy series 
comprising transitional cell cancers (Stein et al 2001). Extended radical lymphadenectomy in 
treatment of SACB assures the removal of many nodal cancer deposits increases the accuracy 
of staging, is likely to result in improved postoperative survival (Ghoneim et al.,1979),  
(Leissner et al., 2004)   Postoperative mortality was 2.6%. They concluded that contemporary 
cystectomy with continent diversion for muscle invasive disease provide minimal morbidity, 
offers good locoregional disease and results  in acceptable quality of life (Abol-enein  et al., 
2004) The results published by others are remarkably similar (Stein et al., 2001, Herr et al., 
2002).  
7.2 Newer prognostic factors 
A more sophisticated procedure may be used to evaluate the likelihood of recurrence or 
progression by DNA ploidy measurement, immunohistochemical staining of the basement 
membrane components, evaluation of cell adherence molecules, growth factors, proteases, 
cell surface antigens and blood group antigens, as well as by the determination of cell-cycle 
related proteins in bladder carcinoma ( Stein et al.,1998; Grossman 1998;  Zlotta & Schulman   
2000,). All of these are experimental and none have reached clinical significance or become 
part of clinical routine. (lokeshwar  et al.,2005).  
8. Future prospects 
SABC is theoretically a good example of a preventable malignant disease, if the parasite could 
be eliminated on a nationwide scale. This is far from being an easy problem. The current 
strategy adopted in Egypt involves a combination of snail control and mass therapy of the 
exposed population. Since screening projects are usually of limited nature, both in time and 
place, they only succeed in lowering the prevalence rate of the disease. There is still much to be 
learned about Schistosomiasis and its control. Other possibilities for bladder cancer prevention 
lie in smoking cessation, reduction of the occupational exposure (mainly to aromatic amines) 
by appropriate regulations and education activities, reduction of infection by Schistosoma 
haematobium (in endemic areas), and promotion of consumption of fruits and vegetables.  
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